Integrated Biopharma, Inc. INBP
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -30.89% | -27.53% | -10.58% | -6.82% | 11.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.89% | -27.53% | -10.58% | -6.82% | 11.21% |
| Cost of Revenue | -23.12% | -16.24% | -1.68% | -4.70% | 10.85% |
| Gross Profit | -98.09% | -117.79% | -97.52% | -25.67% | 14.41% |
| SG&A Expenses | 1.93% | -0.37% | -2.68% | -2.84% | -0.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.50% | -15.26% | -1.76% | -4.58% | 10.06% |
| Operating Income | -247.54% | -246.82% | -552.48% | -66.73% | 46.52% |
| Income Before Tax | -242.86% | -233.03% | -572.43% | -61.11% | 43.72% |
| Income Tax Expenses | -33.25% | -218.56% | -262.32% | -70.20% | 429.45% |
| Earnings from Continuing Operations | -667.42% | -236.99% | -756.90% | -52.51% | -166.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -667.42% | -236.99% | -756.90% | -52.51% | -166.42% |
| EBIT | -247.54% | -246.82% | -552.48% | -66.73% | 46.52% |
| EBITDA | -221.06% | -224.33% | -393.33% | -58.26% | 38.36% |
| EPS Basic | -658.62% | -233.17% | -744.74% | -53.49% | -165.17% |
| Normalized Basic EPS | -235.25% | -236.60% | -500.00% | -62.86% | 41.86% |
| EPS Diluted | -658.62% | -250.00% | -889.47% | -54.65% | -165.17% |
| Normalized Diluted EPS | -235.25% | -241.22% | -509.30% | -62.14% | 45.24% |
| Average Basic Shares Outstanding | 1.47% | 2.50% | 2.93% | 3.19% | 1.70% |
| Average Diluted Shares Outstanding | 1.47% | -1.44% | -0.78% | 2.52% | -0.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |